- জেনেরিক নাম
- Mirabegron
- শক্তি
- 25 mg
- ডোজ ফর্ম
- Tablet (Extended Release)
- প্রস্তুতকারক
- Healthcare Pharmaceuticals Ltd.
- থেরাপিউটিক ক্লাস
- BPH/ Urinary retention/ Urinary incontinence
৳ ২৯.৪ ৳ ৩০.০০ ২% ছাড় প্রতি ইউনিট
দাম হালনাগাদ: ১৮ Nov ২০২৬
বাংলাদেশে Betmira ER 25 mg Tablet (Extended Release) Tablet (Extended Release) হিসেবে পাওয়া যায়; এতে Mirabegron আছে (২৫ mg)। এর থেরাপিউটিক ক্লাস BPH/ Urinary retention/ Urinary incontinence। Betmira ER প্রস্তুত করেছে Healthcare Pharmaceuticals Ltd। Mirabegron-এর অন্য ব্র্যান্ডগুলো এই পাতায় কম দাম থেকে সাজানো আছে, দাম তুলনা করতে পারবেন। দাম: প্রতি ইউনিট ৩০.০০ টাকা। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।
Mirabegron-এর ১০টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। ইউনিট দামের হিসেবে Betmira ER এগুলোর মধ্যে সবচেয়ে কম দামিদের একটি।
Betmira ER is a tablet (extended release) from Healthcare Pharmaceuticals Ltd., with the generic name Mirabegron. Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Use it only as your doctor directs.
Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Your doctor will decide if it is suitable for you.
Betmira ER is taken by mouth. Swallow the tablet (extended release) with water. Take Betmira ER 25 mg tablet (extended release) by mouth as your doctor tells you. Complete the course exactly as prescribed. If you miss a dose, ask your doctor or pharmacist what to do.
Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
Hypertension : Mirabegron can increase blood pressure. There are limited amount of data from the use of Mirabegron in pregnant women. Mirabegron should not be administered during breast-feeding. Tell your doctor about all the other medicines you take.
Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Your doctor will decide if it is suitable for you.
Betmira ER is taken by mouth. Swallow the tablet (extended release) with water.
Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
The listed price is ৳ ৩০.০০.
৳ ২৯.৪ ৳ ৩০.০০ ২% ছাড় প্রতি ইউনিট
দাম হালনাগাদ: ১৮ Nov ২০২৬
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Mirabegron is the first beta-3 adrenoceptor agonist. Mirabegron exerts its effect via a dual mechanism, both directly acts on the bladder smooth muscle and also via the sensory nervous system, it increases the levels of cyclic adenosine monophosphate (cyclic AMP) and leads to relaxation of the detrusor smooth muscle during storage phase of urinary bladder fill-void cycle by activation of beta-3 adrenoceptor which increase bladder capacity.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Adults including elderly: The recommended starting dose is Mirabegron 25 mg tablet once daily with or without food. Based on individual patient efficacy and tolerability the dose may be increased to Mirabegron 50 mg tablet once daily.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Effect of enzyme inhibitors: Mirabegron exposure (AUC) was increased 1.8-fold in the presence of the strong inhibitor of CYP3A/P-gp ketoconazole in healthy volunteers. No dose adjustment is needed when Mirabegron is combined with inhibitors of CYP3A and/or P-gp. However, in patients with mild to moderate renal impairment or mild hepatic impairment concomitantly receiving strong CYP3A inhibitors, such as itraconazole, ketoconazole, ritonavir and clarithromycin, the recommended dose is 25 mg once daily with or without food. Mirabegron is not recommended in patients with severe renal impairment or patients with moderate hepatic impairment concomitantly receiving strong CYP3A inhibitors.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Mirabegron is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients and severe uncontrolled hypertension defined as systolic blood pressure 180 mm Hg and/or diastolic blood pressure 110 mm Hg.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
The most common side effects reported for patients treated with Mirabegron 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections. The frequency of tachycardia was 1.2% in patients receiving Mirabegron 50 mg. Tachycardia led to discontinuation in 0.1% patients receiving Mirabegron 50 mg. The frequency of urinary tract infections was 2.9% in patients receiving Mirabegron 50 mg. Urinary tract infections led to discontinuation in none of the patients receiving Mirabegron 50 mg. Serious adverse reactions included atrial fibrillation (0.2%).এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
There are limited amount of data from the use of Mirabegron in pregnant women. Studies in animals have shown reproductive toxicity. Mirabegron is not recommended during pregnancy and in women is planning to be pregnant. Mirabegron is excreted in the milk of rodents and therefore is predicted to be present in human milk. No studies have been conducted to assess the impact of Mirabegron on milk production in humans, its presence in human breast milk, or its effects on the breast-fed child. Mirabegron should not be administered during breast-feeding. There were no treatment-related effects of Mirabegron on fertility in animals. The effect of Mirabegron on human fertility has not been established.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Renal impairment: Mirabegron has not been studied in patients with end stage renal disease (GFR <15 mL/min/1.73 m2 or patients requiring haemodialysis) and therefore, it is not recommended for use in this patient population. Data are limited in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2); based on a pharmacokinetic study a dose reduction to 25 mg is recommended in this population. Mirabegron is not recommended for use in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2) concomitantly receiving strong CYP3A inhibitors.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Mirabegron has been administered to healthy volunteers at single doses up to 400 mg. At this dose, adverse events reported included palpitations and increased pulse rate exceeding 100 beats per minute (bpm). Multiple doses of Mirabegron up to 300 mg daily for 10 days showed increases in pulse rate and systolic blood pressure when administered to healthy volunteers. Treatment for overdose should be symptomatic and supportive. In the event of overdose, pulse rate, blood pressure, and ECG monitoring is recommended.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Store in a cool and dry place, protected from light.একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।
50 mg
Healthcare Pharmaceuticals Ltd.
৳ ৫৩.৯ ৳ ৫৫.০০ ২% ছাড় প্রতি ইউনিট
ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।